查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472240

色素沉著治療市場：按治療類型、疾病類型和最終用戶：2023-2032 年全球機會分析和產業預測

Hyperpigmentation Treatment Market By Treatment Type, By Disorder Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

預計2022年全球色素沉著治療市場將達51億美元，2023年至2032年複合年成長率為7.5%，到2032年將達到105億美元。

色素沉澱是一種皮膚病，其特徵是皮膚特定區域變黑或變色。當負責膚色的黑色素過度產生並沉積在皮膚上時，就會發生這種現象。色素沉澱的原因有很多，包括黃褐斑、曬傷、發炎後色素沉澱和老齡化。有效的色素沉著管理通常包括使用局部治療、雷射治療、化學換膚，並且經常努力防曬以防止病情進一步惡化。

色素沉著過度治療市場-IMG1

色素沉著治療市場的成長歸因於全球美容標準的變化和老年人口的快速成長。近年來，社會對美麗的認知發生了顯著變化，潔淨、均勻的肌膚變得更加重要。因此，人們都在努力追求更完美的膚色，導致對色素沉著治療的需求不斷成長。在媒體影響和社交平台普及的推動下，不斷變化的美容標準創造了一種文化，將一塵不染的皮膚視為健康和吸引力的象徵。隨著人們尋求有效的解決方案來解決皮膚變色問題並實現所需的美感，這種文化轉變導致色素沉著治療的採用激增。因此，全球美容標準的變化預計將推動色素沉著治療市場的成長。

此外，老年人口的快速成長預計也將顯著促進市場成長。例如，美國人口普查局報告稱，2020 年老年人口將達到 5,580 萬人。隨著世界人口結構的不斷發展和老年人比例的增加，色素沉澱的發生率將變得更高。色素沉澱的特徵是皮膚變黑，是老年人常見的皮膚病問題，通常是由於陽光照射、老齡化相關的變化和潛在的醫療狀況等因素造成的。人口老化正在尋求改善皮膚外觀和解決色素沉著不規則問題的解決方案，這推動了對先進和有針對性的色素沉著治療的需求。製藥和護膚行業開發了專門為滿足老齡化人口的獨特需求而設計的創新產品和治療方法。然而，與化學換膚和光療相關的副作用正在限制市場的成長。

色素沉著治療市場按治療類型、疾病類型、最終用戶和地區進行細分。依治療類型分類，市場分為外用製劑、光療和微晶換膚。依疾病類型，市場分為老年斑​​、黃褐斑等。其他症狀包括發炎後色素沉著和痤瘡疤痕。依最終使用者分為醫院、皮膚科診所等。依地區分類，我們有北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家地區）、亞太地區（日本、中國、澳洲、印度、韓國、其他亞洲地區）太平洋地區）和拉丁美洲（巴西、哥倫比亞、阿根廷和其他拉丁美洲地區）和中東/非洲A（海灣合作理事會、南美、北非和其他中東/非洲A 地區）。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年色素沉著治療市場分析的細分市場、當前趨勢、估計/趨勢和動態的定量分析，並確定了主要的色素沉著治療市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 對色素沉著治療市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前位置的清晰了解。
  • 該報告包括對區域和全球色素沉著治療市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

可使用此報告進行客製化（請聯絡銷售人員以了解額外費用和時間表）

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章色素沉澱治療市場：依治療類型

  • 概述
  • 局部劑
  • 光療
  • 微晶換膚

第5章色素沉著治療市場：依疾病類型

  • 概述
  • 老人斑
  • 黃褐斑
  • 其他

第6章色素沉澱治療市場：依最終使用者分類

  • 概述
  • 醫院
  • 皮膚科診所
  • 其他

第7章色素強化治療市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • GCC
    • 南非
    • 北非
    • 其他中東/非洲

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Episciences Inc
  • Vivier Pharma
  • Pierre Fabre SA
  • L'Oreal Group
  • Areolase Corporation
  • Lyma
  • Trophy Skin
  • Bio Italica
  • PCA Skin
  • Procter & Gamble
Product Code: A186336

The global hyperpigmentation treatment market was valued at $5.1 billion in 2022, and is projected to reach $10.5 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032. Hyperpigmentation is a dermatological condition characterized by the darkening or discoloration of certain areas of the skin. This phenomenon occurs when an excess amount of melanin, the pigment responsible for skin color, is produced and deposited in the skin. There are various causes of hyperpigmentation such as Melasma, sun exposure, post inflammatory hyperpigmentation, and age factor. Effective management of hyperpigmentation often involves the use of topical treatments, laser therapy, or chemical peels, along with diligent sun protection to prevent further exacerbation of the condition

Hyperpigmentation Treatment Market - IMG1

The hyperpigmentation treatment market growth is attributed to changes in beauty standards globally, and surge in geriatric population. In recent years, there has been a notable shift in societal perceptions of beauty, with an increasing emphasis on clear, even-toned skin. As a result, individuals are now more inclined toward achieving a flawless complexion, contributing to the heightened demand for hyperpigmentation treatments. The evolving beauty standards, fueled by media influence and the pervasive use of social platforms, have created a culture where blemish-free skin is considered a symbol of health and attractiveness. This cultural shift has led to a surge in the adoption of hyperpigmentation treatments as people seek effective solutions to address skin discoloration issues and attain the desired aesthetic. Thus, the change in beauty standards globally is expected to drive the growth of the hyperpigmentation treatment market.

In addition, the surge in geriatric population is expected to significantly contribute to the growth of the market. For instance, according to the U.S. Census Bureau, it was reported that the older population reached 55.8 million in 2020. As the global demographic landscape continues to evolve, with an increasing proportion of elderly individuals, the incidence of hyperpigmentation disorders becomes more prevalent. Hyperpigmentation, characterized by darkened areas of the skin, is a common dermatological concern among the elderly, often attributed to factors such as sun exposure, age-related changes, and underlying medical conditions. The geriatric population seeking solutions to enhance skin appearance and address pigmentation irregularities, has fueled the demand for advanced and targeted hyperpigmentation treatments. The pharmaceutical and skincare industries have developed innovative products and therapies specifically tailored to cater to the unique needs of the aging population. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market.

The hyperpigmentation treatment market is segmented on the basis of treatment type, disorder type, end user, and region. By treatment type, the market is classified into topical agent, photo therapy, and microdermabrasion. By disorder type, the market is divided into age spots, melasma, and others. Others include post-inflammatory hyperpigmentation and acne scars. By end user, it is segregated into hospitals, dermatological clinics, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the hyperpigmentation treatment market are Episciences Inc, Vivier Pharma, Pierre Fabre S.A, L'Oreal Paris, Areolase Corporation, Lyma, Trophy Skin, Bio Italica, PCA Skin and Procter & Gamble. Key players have adopted product launch as a key developmental strategy to improve the product portfolio of the hyperpigmentation treatment market

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperpigmentation treatment market analysis from 2022 to 2032 to identify the prevailing hyperpigmentation treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hyperpigmentation treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hyperpigmentation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Treatment Type

  • Topical Agent
  • Photo Therapy
  • Microdermabrasion

By Disorder Type

  • Age Spot
  • Melasma
  • Other

By End User

  • Hospitals
  • Dermatological clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Episciences Inc
    • Vivier Pharma
    • Pierre Fabre S.A
    • L'Oreal Group
    • Areolase Corporation
    • Lyma
    • Trophy Skin
    • Bio Italica
    • PCA Skin
    • Procter & Gamble

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Topical Agent
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Photo Therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Microdermabrasion
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Age Spot
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Melasma
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Other
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HYPERPIGMENTATION TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Dermatological clinics
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: HYPERPIGMENTATION TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Treatment Type
    • 7.2.3. Market size and forecast, by Disorder Type
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Treatment Type
      • 7.2.5.1.2. Market size and forecast, by Disorder Type
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Treatment Type
      • 7.2.5.2.2. Market size and forecast, by Disorder Type
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Treatment Type
      • 7.2.5.3.2. Market size and forecast, by Disorder Type
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Treatment Type
    • 7.3.3. Market size and forecast, by Disorder Type
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Treatment Type
      • 7.3.5.1.2. Market size and forecast, by Disorder Type
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Treatment Type
      • 7.3.5.2.2. Market size and forecast, by Disorder Type
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Treatment Type
      • 7.3.5.3.2. Market size and forecast, by Disorder Type
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Treatment Type
      • 7.3.5.4.2. Market size and forecast, by Disorder Type
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Treatment Type
      • 7.3.5.5.2. Market size and forecast, by Disorder Type
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Treatment Type
      • 7.3.5.6.2. Market size and forecast, by Disorder Type
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Treatment Type
    • 7.4.3. Market size and forecast, by Disorder Type
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Treatment Type
      • 7.4.5.1.2. Market size and forecast, by Disorder Type
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Treatment Type
      • 7.4.5.2.2. Market size and forecast, by Disorder Type
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Treatment Type
      • 7.4.5.3.2. Market size and forecast, by Disorder Type
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Treatment Type
      • 7.4.5.4.2. Market size and forecast, by Disorder Type
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Treatment Type
      • 7.4.5.5.2. Market size and forecast, by Disorder Type
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Treatment Type
      • 7.4.5.6.2. Market size and forecast, by Disorder Type
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Treatment Type
    • 7.5.3. Market size and forecast, by Disorder Type
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Treatment Type
      • 7.5.5.1.2. Market size and forecast, by Disorder Type
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Treatment Type
      • 7.5.5.2.2. Market size and forecast, by Disorder Type
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Treatment Type
      • 7.5.5.3.2. Market size and forecast, by Disorder Type
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Treatment Type
      • 7.5.5.4.2. Market size and forecast, by Disorder Type
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Treatment Type
    • 7.6.3. Market size and forecast, by Disorder Type
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Treatment Type
      • 7.6.5.1.2. Market size and forecast, by Disorder Type
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Treatment Type
      • 7.6.5.2.2. Market size and forecast, by Disorder Type
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Treatment Type
      • 7.6.5.3.2. Market size and forecast, by Disorder Type
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Treatment Type
      • 7.6.5.4.2. Market size and forecast, by Disorder Type
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Episciences Inc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Vivier Pharma
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pierre Fabre S.A
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. L'Oreal Group
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Areolase Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Lyma
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Trophy Skin
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Bio Italica
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. PCA Skin
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Procter & Gamble
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 06. HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. HYPERPIGMENTATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. UK HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 39. UK HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 61. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 91. GCC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. GCC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 93. GCC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. EPISCIENCES INC: KEY EXECUTIVES
  • TABLE 104. EPISCIENCES INC: COMPANY SNAPSHOT
  • TABLE 105. EPISCIENCES INC: PRODUCT SEGMENTS
  • TABLE 106. EPISCIENCES INC: SERVICE SEGMENTS
  • TABLE 107. EPISCIENCES INC: PRODUCT PORTFOLIO
  • TABLE 108. EPISCIENCES INC: KEY STRATERGIES
  • TABLE 109. VIVIER PHARMA: KEY EXECUTIVES
  • TABLE 110. VIVIER PHARMA: COMPANY SNAPSHOT
  • TABLE 111. VIVIER PHARMA: PRODUCT SEGMENTS
  • TABLE 112. VIVIER PHARMA: SERVICE SEGMENTS
  • TABLE 113. VIVIER PHARMA: PRODUCT PORTFOLIO
  • TABLE 114. VIVIER PHARMA: KEY STRATERGIES
  • TABLE 115. PIERRE FABRE S.A: KEY EXECUTIVES
  • TABLE 116. PIERRE FABRE S.A: COMPANY SNAPSHOT
  • TABLE 117. PIERRE FABRE S.A: PRODUCT SEGMENTS
  • TABLE 118. PIERRE FABRE S.A: SERVICE SEGMENTS
  • TABLE 119. PIERRE FABRE S.A: PRODUCT PORTFOLIO
  • TABLE 120. PIERRE FABRE S.A: KEY STRATERGIES
  • TABLE 121. L'OREAL GROUP: KEY EXECUTIVES
  • TABLE 122. L'OREAL GROUP: COMPANY SNAPSHOT
  • TABLE 123. L'OREAL GROUP: PRODUCT SEGMENTS
  • TABLE 124. L'OREAL GROUP: SERVICE SEGMENTS
  • TABLE 125. L'OREAL GROUP: PRODUCT PORTFOLIO
  • TABLE 126. L'OREAL GROUP: KEY STRATERGIES
  • TABLE 127. AREOLASE CORPORATION: KEY EXECUTIVES
  • TABLE 128. AREOLASE CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. AREOLASE CORPORATION: PRODUCT SEGMENTS
  • TABLE 130. AREOLASE CORPORATION: SERVICE SEGMENTS
  • TABLE 131. AREOLASE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 132. AREOLASE CORPORATION: KEY STRATERGIES
  • TABLE 133. LYMA: KEY EXECUTIVES
  • TABLE 134. LYMA: COMPANY SNAPSHOT
  • TABLE 135. LYMA: PRODUCT SEGMENTS
  • TABLE 136. LYMA: SERVICE SEGMENTS
  • TABLE 137. LYMA: PRODUCT PORTFOLIO
  • TABLE 138. LYMA: KEY STRATERGIES
  • TABLE 139. TROPHY SKIN: KEY EXECUTIVES
  • TABLE 140. TROPHY SKIN: COMPANY SNAPSHOT
  • TABLE 141. TROPHY SKIN: PRODUCT SEGMENTS
  • TABLE 142. TROPHY SKIN: SERVICE SEGMENTS
  • TABLE 143. TROPHY SKIN: PRODUCT PORTFOLIO
  • TABLE 144. TROPHY SKIN: KEY STRATERGIES
  • TABLE 145. BIO ITALICA: KEY EXECUTIVES
  • TABLE 146. BIO ITALICA: COMPANY SNAPSHOT
  • TABLE 147. BIO ITALICA: PRODUCT SEGMENTS
  • TABLE 148. BIO ITALICA: SERVICE SEGMENTS
  • TABLE 149. BIO ITALICA: PRODUCT PORTFOLIO
  • TABLE 150. BIO ITALICA: KEY STRATERGIES
  • TABLE 151. PCA SKIN: KEY EXECUTIVES
  • TABLE 152. PCA SKIN: COMPANY SNAPSHOT
  • TABLE 153. PCA SKIN: PRODUCT SEGMENTS
  • TABLE 154. PCA SKIN: SERVICE SEGMENTS
  • TABLE 155. PCA SKIN: PRODUCT PORTFOLIO
  • TABLE 156. PCA SKIN: KEY STRATERGIES
  • TABLE 157. PROCTER & GAMBLE: KEY EXECUTIVES
  • TABLE 158. PROCTER & GAMBLE: COMPANY SNAPSHOT
  • TABLE 159. PROCTER & GAMBLE: PRODUCT SEGMENTS
  • TABLE 160. PROCTER & GAMBLE: SERVICE SEGMENTS
  • TABLE 161. PROCTER & GAMBLE: PRODUCT PORTFOLIO
  • TABLE 162. PROCTER & GAMBLE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF HYPERPIGMENTATION TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN HYPERPIGMENTATION TREATMENT MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL HYPERPIGMENTATION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. HYPERPIGMENTATION TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. GCC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022